Targeted Therapy & Precision Oncology
Part of Healthcare - Oncology
| Ticker | Company | Mkt Cap▼ | Price | Chg% | Volume |
|---|---|---|---|---|---|
 LLY | Eli Lilly & Co. | $0.8t | $871.50 | -1.4% | 2.7M |
 RVMD | Revolution Medicines, Inc. Common Stock | $18.4b | $131.79 | -2.6% | 4.8M |
 INCY | Incyte Genomics Inc | $18.0b | $95.70 | +1.1% | 2.1M |
 JAZZ | Jazz Pharmaceuticals, Inc. | $11.3b | $201.26 | +2.4% | 1.3M |
 EXEL | Exelixis Inc | $10.9b | $44.65 | -0.6% | 2.1M |
 NUVL | Nuvalent, Inc. Class A Common Stock | $7.6b | $104.04 | -0.4% | 491.4K |
 HALO | Halozyme Therapeutics, Inc. | $7.4b | $64.49 | -1.3% | 1.3M |
 COGT | Cogent Biosciences, Inc. Common Stock | $5.7b | $36.60 | -0.6% | 1.0M |
 CELC | Celcuity Inc. Common Stock | $5.2b | $125.75 | +3.9% | 995.4K |
 ERAS | Erasca, Inc. Common Stock | $4.6b | $15.82 | -26.4% | 22.6M |
 CORT | Corcept Therapeutics Inc. | $4.1b | $46.20 | +0.3% | 646.7K |
 IDYA | IDEAYA Biosciences, Inc. Common Stock | $2.8b | $29.46 | -4.1% | 961.4K |
 TNGX | Tango Therapeutics, Inc. | $2.7b | $26.36 | +2.3% | 2.7M |
 ELVN | Enliven Therapeutics, Inc. Common Stock | $2.6b | $44.89 | +1.4% | 629.4K |
 DAWN | Day One Biopharmaceuticals, Inc. Common Stock | $2.2b | $21.52 | -0.0% | 3.0M |
 IMNM | Immunome, Inc. | $2.2b | $23.50 | -0.3% | 1.1M |
 TYRA | Tyra Biosciences, Inc. Common Stock | $1.9b | $36.92 | -1.8% | 882.8K |
 ZYME | Zymeworks Inc. | $1.8b | $28.55 | +1.6% | 950.2K |
 RLAY | Relay Therapeutics, Inc. Common Stock | $1.7b | $14.94 | -1.3% | 4.1M |
 NRIX | Nurix Therapeutics, Inc. Common stock | $1.5b | $16.49 | -1.1% | 615.6K |
 DMRA | Damora Therapeutics, Inc. Common Stock | $1.5b | $25.56 | +3.3% | 267.3K |
 NUVB | Nuvation Bio Inc. | $1.4b | $4.59 | -6.1% | 6.6M |
 ORIC | Oric Pharmaceuticals, Inc. Common Stock | $1.4b | $10.21 | -0.3% | 1.4M |
 VIR | Vir Biotechnology, Inc. Common Stock | $1.4b | $10.64 | +2.7% | 1.8M |
 GLUE | Monte Rosa Therapeutics, Inc. Common Stock | $1.2b | $19.32 | -2.4% | 598.3K |
 BHVN | Biohaven Ltd. | $1.2b | $9.59 | -2.9% | 1.4M |
 NVCR | NovoCure Limited Ordinary Shares | $1.2b | $12.49 | +0.2% | 868.6K |
 OLMA | Olema Pharmaceuticals, Inc. Common Stock | $1.2b | $15.30 | -1.4% | 720.5K |
 AVBP | ArriVent BioPharma, Inc. Common Stock | $0.9b | $30.30 | -0.4% | 683.7K |
 GERN | Geron Corp | $0.9b | $1.52 | +1.3% | 12.3M |
 URGN | UroGen Pharma Ltd. Ordinary Shares | $0.8b | $23.76 | -1.4% | 442.2K |
 BBOT | BridgeBio Oncology Therapeutics, Inc. Common Stock | $0.7b | $8.79 | +0.1% | 525.4K |
 KURA | Kura Oncology, Inc. | $0.7b | $9.08 | -1.9% | 872.8K |
 RLMD | Relmada Therapeutics, Inc. Common Stock | $0.7b | $7.03 | -2.6% | 1.4M |
 ARVN | Arvinas, Inc | $0.7b | $10.30 | -1.3% | 425.3K |
 RIGL | Rigel Pharmaceuticals Inc. (New) | $475.1m | $30.48 | +0.6% | 200.3K |
 ADCT | ADC Therapeutics SA | $462.4m | $3.76 | -4.6% | 770.8K |
 VSTM | Verastem, Inc. | $426.0m | $5.53 | -6.4% | 1.4M |
 STRO | Sutro Biopharma, Inc. | $399.3m | $33.48 | +0.5% | 190.7K |
 MNPR | Monopar Therapeutics Inc. Common Stock | $356.6m | $53.98 | +1.5% | 67.3K |
 IMRX | Immuneering Corporation Class A Common Stock | $315.5m | $5.75 | -4.8% | 761.3K |
 PBYI | PUMA BIOTECHNOLOGY INC | $311.9m | $7.49 | -0.7% | 193.1K |
 DCTH | Delcath Systems Inc | $308.9m | $10.85 | +0.0% | 231.9K |
 CCCC | C4 Therapeutics, Inc. | $229.3m | $2.84 | -1.4% | 1.2M |
 TLSI | TriSalus Life Sciences, Inc. Common Stock | $227.4m | $4.51 | -2.8% | 117.7K |
 NVCT | Nuvectis Pharma, Inc. Common Stock | $198.4m | $8.81 | -1.0% | 35.1K |
 PRLD | Prelude Therapeutics Incorporated | $193.4m | $4.50 | -4.3% | 586.5K |
 NTHI | NeOnc Technologies Holdings, Inc. Common Stock | $171.6m | $4.67 | -2.3% | 110.9K |
 WHWK | Whitehawk Therapeutics, Inc. Common Stock | $154.8m | $4.17 | +3.5% | 161.6K |
 CRBP | Corbus Pharmaceuticals Holdings, Inc. | $152.5m | $10.07 | +0.1% | 458.1K |